Table 5.
Studies of stereotactic body radiotherapy (SBRT) for Adrenal Gland Metastasis.
| Study (year) | Number of Patients (Lesions) | Primary Tumor Site | GTV-to-CTV Margin | SBRT Schedule | Prescription | Median Follow-Up | LC | OS |
|---|---|---|---|---|---|---|---|---|
| Holy et al 7 (2011) | 18 (18) | Lung 100% | 2 mm | 15-40 Gy/ 3-12 Fr | 100% isodose line | 21 months | 77% (objective response rate) | 23 months (median) |
| Scorsetti et al 8 (2011) | 34 (36) | Lung 71% | 3 mm | 32 Gy/4 Fr (median) | 95% isodose line | 41 months | 66% (1 year) | 22 months (median) |
| Casamassima et al 6 (2012) | 48 (NR) | Lung 50% | 0 mm | 34.9 Gy /3 Fr (mean) SRS: 23.5 Gy (mean) |
70% isodose line | 16.2 months | 90% (1 year) | 39.7% (1 year) |
| Ahmed et al 9 (2013) | 13 (13) | Lung 46% | 0 mm | 45 Gy/5 Fr (median) | NR | 12.3 months | 100% (crude rate) | 62.9% (1 year) 7.2 month (median) |
| Rudra et al 14 (2013) | 10 (13) | Lung 80% | 0 mm | 36 Gy/3 Fr (median) | 80%-90% isodose line | 14.9 months | 73% (1 year) | 90% (1 year) 17.3 month (median) |
| Celik et al 16 (2017) | 15 (15) | Lung 100% | 0 mm | 42Gy/6 Fr | 65% isodose line | 24 months | 60% (1 year) | 93.3% (1 year) |
| Franzese et al 17 (2017) | 46 (46) | Lung 65.2% | 0 mm | 40 Gy/4 Fr | CTV V98% > 98% | 7.6 months | 65.5% (1 year) | 87.6% (1 year) |
| This study | 20 (21) | Lung 45% | 0 or 3 mm | 48 Gy/8 Fr (median) | Isocenter, PTVD95 | 17.5 months | 91.7% (1 year) | 78.5% (1 year) |
Abbreviations: CTV, clinical target volume; Dxx, xx% of the PTV volume received by the dose; Fr, fractions; GTV, gross tumor volume; LC, local control; NR, data not reported; OS, overall survival; PTV, planning target volume; SBRT, stereotactic body radiotherapy.